MOBILion Systems, Inc., a pioneer in fast, efficient, high-resolution instrumentation for biomarker discovery, diagnostics and therapeutic development, is collaborating with an international research team to identify alterations in the metabolism of selective glycosphingolipids in specific brain regions that contribute to the early onset and progression of Parkinson’s disease.
London – Arena International announced today the first-ever Direct-to-Patient and Virtual Clinical Trials (https://arena-international.com/dtpvirtual/) will be held as a Digital Experience on Thursday, 9 July 2020. As COVID-19 has forced the market to move towards decentralized and remote models, this event provides the perfect opportunity for clinical trial professionals to hear, meet and learn from top-class speakers around the world to discuss challenges and innovations in this critical time.
Chadds Fords, PA, June 5 2020: MOBILion Systems, Inc. is showcasing its first ion mobility separations product to the biopharma drug development and academic research markets, with data from its first beta users, during the American Society for Mass Spectrometry’s (ASMS) virtual conference.
Personalized medicine has become a paradigm-shifting trend in healthcare - the hegemony of “one-size-fits-all” drugs is increasingly challenged by novel innovative modalities and therapies, laser-sharped for a specific group of patients, or even a single patient in some cases. This is a complex story, and the progress in personalized medicine will take time and tectonic shifts in the pharmaceutical research workflow.
On the other hand, the advent of personalized medicine is only possible with a more personalized system for health assessment, new robust biomarkers, and novel approaches to run and monitor clinical trials. This will require diagnostics that can provide sufficient insight into the metabolic status of individuals, and relatively new science of metabolomics is now taking off in the biotech industry.